Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Amgen’s Prolia/Xgeva (denosumab) could have another use in a rare bone disease, according to a small NIH-funded Phase II study, adding …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
